Mexico plans to buy 35 million COVID-19 vaccines from China

Mexico plans to buy 35 million COVID-19 vaccines from China

Mexico plans to buy 35 million COVID-19 vaccines from China.  China CanSino COVID-19 vaccine was approved for emergency vaccination in Mexico, and its stock price has skyrocketed, with a total market value of over 100 billion.

Hong Kong-listed Cansino Biological Co., Ltd. issued an announcement on the 10th that the adenovirus vector COVID-19 vaccine (Ad5-nCoV) developed by the company and the team of Academician Chen Wei was urgently used by the Mexican Federal Health Risk Protection Committee on the 9th local time. Authorized to vaccinate adults 18 years and older in the country. In October last year, CanSino Biotech signed a pre-purchase framework agreement with the Mexican Ministry of Health, planning to supply Mexico with 35 million doses of COVID-19 vaccine.

On February 10, Kansino Biosciences continued to rise and closed the daily limit, an increase of 20%, setting a new record high, and the total market value exceeded 100 billion Hong Kong dollars.

According to the guidelines of the World Health Organization, a COVID-19vaccine with a protective effect of more than 50% is considered effective. Ad5-nCoV is immunized with a single injection. According to the results of Phase I and Phase II clinical trials published by Cansino in the medical journal “The Lancet”, the data fully proves that the low-dose vaccine is safe, and one injection of vaccination causes significant immunogenicity. Stimulates balanced humoral immunity and cellular immunity. No serious adverse reaction has been found in volunteers.

In addition, because this vaccine uses the adenovirus vector technology route, it can be stored stably between 2°C and 8°C, like the Ebola virus disease vaccine developed by the same technology route, and is stable and easier to transport normally. And storage, the vaccine is more accessible. At the same time, the vaccine can be administered in a variety of ways, including intramuscular injection or mucosal immunization.

Public information shows that the Phase III clinical trial of Ad5-nCoV has been completed in 78 clinical research centers in Pakistan, Mexico, Russia, Chile, Argentina and other countries in three continents in September 2020, and completed more than 40,000 subjects. Vaccination, the trial is jointly led by global PI, global co-PI, and country co-PI from seven countries, and follows strict ethics Standards and rigorous scientific guidelines.

The Phase III clinical trial of Ad5-nCoV is a global multicenter, randomized, double-blind, placebo-controlled, adaptive trial designed to evaluate the effectiveness and safety of the Ad5-nCoV vaccine in healthy adults 18 years of age and older And immunogenicity. All subjects received a dose of Ad5-nCoV or placebo on day 0, and followed up the effectiveness of the vaccine and SAE during a 52-week period.

According to media reports, Faisal Sultan, Special Assistant to the Prime Minister for National Health Affairs of Pakistan, announced on February 8 local time that Consino’s COVID-19 vaccine ConvideciaTM (ConvideciaTM) has launched a global multi-center phase three. Interim data from clinical trials showed that 28 days after a single injection of the vaccine in Pakistan, the protective effect against severe new coronavirus pneumonia was 100%, and the overall protective effect was 74.8%. No serious adverse reactions related to the vaccine occurred. Global data show that 28 days after a single injection of the vaccine, the protective effect against severe new coronavirus pneumonia is 90.98%, and the overall protective effect is 65.7%.

Up to now, there are more than one hundred vaccines in the preclinical or clinical trial stage. In addition to CanSino’s human type 5 adenovirus vector COVID-19 vaccine, the chimpanzee adenovirus vector COVID-19 vaccine developed by Oxford University and AstraZeneca is jointly developed by the Russian R&D team Gamaleya developed adenovirus vector vaccines based on serotype 26 (rAd26-S) and serotype 5 (rAd5-S), and Johnson & Johnson developed adenovirus vector vaccines based on serotype 26 (Ad26).

(source:internet, reference only)

Disclaimer of medicaltrend.org